TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00799760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir + zanamivir
Description: oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir + zanamivir's placebo
Description: oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir's placebo + zanamivir
Description: oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
Study: NCT04570514

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention (PCI)

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention (PCI)
Study: NCT03967509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comet
Study: NCT00900445

Intervention type: DRUG
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Intervention: Prednisolone
Description: Given orally

Intervention type: DRUG
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04766736

Intervention type: PROCEDURE
Intervention: Quantification of netrin-1 signals by antibody-based approaches
Description: Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Intervention type: PROCEDURE
Intervention: Quantification of netrin-1 signals by antibody-based approaches
Description: Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
Study: NCT03914950

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT results with TOF/without TOF
Description: Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas.
Study: NCT01289665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lubricating gel used during speculum insertion.
Description: Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water used during speculum examination.
Description: Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
Study: NCT01046266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: 700mg iv weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
Study: NCT00773734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Study: NCT02717858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c./subcutaneously (under the skin) once daily.
Study: NCT03547336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX800 Dialyzer
Description: Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
Study: NCT02439671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McGill Transition Support Program
Description: The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages.
Study: NCT04334486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super Smash Brothers Melee (Gamecube)
Description: 10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
Study: NCT00688376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Description: During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Study: NCT01150617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine plus insulin analogues
Description: * Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine plus insulin analogues
Description: * Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up.
Study: NCT04160429

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of sweat, saliva, and blood samples

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study: NCT01233648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rate control via CRT-D and AVN ablation
Description: rate control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhythm control via pharmacologic, electrical or ablative therapies
Description: rhythm control
Study: NCT01836406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine and remote ischemic preconditioning
Description: Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
Study: NCT04530240

Intervention type: PROCEDURE
Intervention: Liver Transplantation
Description: Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.

Intervention type: PROCEDURE
Intervention: Liver Transplantation
Description: Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
Study: NCT04050150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm training in standing
Description: Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
Study: NCT01711528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05123014

Intervention type: OTHER
Group type: OTHER
Intervention: relex smile
Description: In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
Study: NCT01020461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein
Description: Accuvein will be used to facilitate venous blood sampling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein
Description: Accuvein will be used to facilitate peripheral IV catheter placement
Study: NCT04317235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Is to put 3 ml or 5 ml and show the difference

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Is to put 3 ml or 5 ml and show the difference
Study: NCT00702832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: treatment as usual
Study: NCT04256187

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
Study: NCT01884363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Once ounce per day of walnuts
Study: NCT01550601

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric surgery
Description: The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
Study: NCT04160429

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04126707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HQP1351
Description: Orally, single dose of 30mg
Study: NCT02677129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based exercise intervention
Description: Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
Study: NCT01791816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Ng-monomethyl Arginine (L-NMMA)
Description: Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
Study: NCT01244672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferguson
Description: This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THD
Description: Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
Study: NCT03067116

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography Evaluation
Description: Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometrics
Description: measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitals
Description: measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability

Intervention type: OTHER
Intervention: Health and daily activity questionnaires
Description: one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
Study: NCT05749523

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Exercise vs non-exercise
Study: NCT02639975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: once daily oral administration
Study: NCT00297856

Intervention type: BIOLOGICAL
Intervention: Boostrix®
Description: Single dose

Intervention type: BIOLOGICAL
Intervention: Td (Tetanus diphtheria) vaccine
Description: Single dose
Study: NCT04567030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental monitoring (DM)
Description: DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental monitoring (DM)
Description: DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
Study: NCT00557076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Auditory Sensory Training
Description: Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Auditory Sensory Training
Description: The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
Study: NCT00321828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
Study: NCT02887300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review.
Study: NCT00757848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 60 mg, oral tablet, twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD9668 Placebo equivalent
Description: Match placebo to 60 mg, oral tablet, twice daily for 28 days
Study: NCT01207648

Intervention type: DRUG
Intervention: Rebif®
Description: This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
Study: NCT02938403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo counseling
Description: Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Counseling
Description: Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
Study: NCT00506129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Transplant
Description: Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.